Starton Therapeutics, Inc.

Lexeo Therapeutics Inc. became the 20th biopharma to launch an initial public offering in the US on 2 November when it sold 9.09 million shares at $11 each to gross $100m in its late-night public mar

The two biggest biopharmaceutical initial public offerings in the US so far in 2023 occurred during the first week of May, although the largest of the two was a consumer health care spinout from a dru

Zydus Lifesciences Limited expects to begin chipping away at Bristol Myers Squibb Company ’s Revlimid (lenalidomide) franchise in the US, the latter’s best-selling immunomodulatory drug, in the near

Zydus Lifesciences Limited expects to begin chipping away at Bristol Myers Squibb Company ’ Revlimid (lenalidomide) franchise in the US, the latter’s best-selling immunomodulatory drug, in the near